



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

September 10, 2013 6:00 – 8:30 p.m.

- 1. Executive Session 6:00 - 6:30**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates 6:35 - 6:45**
 - Updates

- 4. Medical Director Update 6:45 - 6:50**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings 6:50 - 7:05**
 - Pediatric Antipsychotic Medications

- 6. RetroDUR/DUR 7:05 – 7:20**
 - Discussion of Possible Topics for Coming Year

- 7. Clinical Update: Drug Reviews 7:20 – 8:00**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Abilify[®] Maintena (aripiprazole) Intramuscular Injection
 - Lotemax[®] (loteprednol) Ophthalmic Gel
 - Uceris[®] (budesonide) ER Oral Tablets

 - Full New Drug Reviews**
 - Gattex[®] (teduglutide) Subcutaneous Injection
 - Juxtapid[®] (lomitapide) Oral Capsule
 - Kynamro[®] (mipomersen) Subcutaneous Injection
 - Nesina[®], Oseni[®] & Kazano[®] (alogliptin, alogliptin/pioglitazone & alogliptin/metformin) Oral Tablets
 - Signifor[®] (pasireotide) Subcutaneous Injection
 - Vascepa[®] (icosapent ethyl) Oral Capsule

- 8. Therapeutic Drug Classes – Periodic Review 8:00 – 8:10**
(Public comment prior to Board action)
Class review documents available on DVHA web site 09/10/2013 @ Noon
 - Antivirals: Oral
 - Antivirals: Topical

- 9. New Managed Therapeutic Drug Classes** **8:10– 8:15**
(Public comment prior to Board action)
- Epinephrine Auto-injector
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:15 – 8:25**
(Public comment prior to Board action)
- Crinone[®]
 - Makena[®]
 - Second Generation Cephalosporins
- 11. General Announcements** **8:25– 8:30**
Selected FDA Safety Alerts
- Acetaminophen: Drug Safety Communication - Association with Risk of Serious Skin Reactions
 - Gilenya: Drug Safety Communication - Possible PML Case in Europe
 - Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
 - Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection
- 12. Adjourn** **8:30**